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Summary
 
Objectives
 
Elevated circulating androgens are risk factors for
several chronic, metabolic and reproductive disorders. Metformin
is an insulin-sensitizing agent that may lower androgen levels. To
evaluate the effects of metformin on endogenous androgens
and SHBG levels in women, we conducted a systematic review and
meta-analysis of randomized controlled trials (RCTs) comparing
metformin with placebo or no treatment.
 
Data source
 
We used OVID to search MEDLINE, EMBASE and
CENTRAL until March 2007.
 
Review methods
 
Two reviewers independently extracted data on
methodological quality, participants, interventions and outcomes
of interest. Our a priori primary outcome was post-treatment
measurements. In a secondary analysis, we evaluated the difference
between the pre- and post-treatment levels. We computed the
weighted mean difference (WMD) as a measure of effect for each
outcome using the DerSimonian–Laird random effects method. We
used the I
 
2
 
 statistic to assess heterogeneity and explored its causes
in subgroup analyses of features related to participants’ characteristics
and study design. Based on a regression model, we conducted
sensitivity analyses by investigating the use of placebo as a predictor
of effect size.
 
Results
 
Twenty RCTs fulfilled the inclusion criteria. Pooled WMDs
in post-treatment levels between the metformin and control group
were –0·31 nmol/l (95% CI –0·65 to 0·03) for total testosterone (TT),
0·10 pmol/l (95% CI –0·89 to 1·10) for free testosterone (FT),
0·14 
 
μ
 
mol/l (95% CI –0·34 to 0·62) for dehydroepiandrosteronesulfate
(DHEAS), –0·60 nmol/l (95% CI –1·67 to 0·46) for androstenedione
(AND) and 5·88 nmol/l (95% CI 2·01–9·75) for SHBG. Pooled
WMDs of the pre- to post-treatment differences (i.e. with
adjustment for baseline hormone levels) were –0·38 (95% CI –0·51
to –0·25) for TT, –2·71 (95% CI –10·35 to 4·93) for FT, –0·50 (95% CI
–0·83 to –0·16) for DHEAS, –1·39 (95% CI –2·30 to –0·49) for AND
and 6·63 (95% CI 2·32–10·94) for SHBG. In subgroup analyses,
features related to the administered treatment (i.e. metformin as a
single agent or as part of combined regimens) partly explained
the heterogeneity. Sensitivity analyses of studies using placebo
showed similar results to those not using placebo.
 
Conclusions
 
Our systematic review and meta-analysis provides
evidence of metformin-induced changes in circulating androgens
and SHBG levels in women but the quality of evidence is not high.
However, there are no data from RCTs regarding these effects in
postmenopausal women or healthy premenopausal women. High-
quality RCTs are required to evaluate whether metformin has effects
on surrogate markers and patient-important outcomes in these
patient groups.
(Received 24 January 2008; returned for revision 21 February 2008; 
 
finally revised 6 August 2008; accepted 13 October 2008)
 
Introduction
 
Metformin is an insulin-sensitizing agent with several mechanisms
of action. It decreases hepatic glucose production and insulin
secretion, enhances peripheral glucose uptake by muscles, and
increases glucose oxidation by adipose tissue.
 
1,2
 
 These mechanisms
combined improve insulin resistance and blood glucose control.
 
1,3,4
 
The clinical indications for metformin therapy include several
disorders, such as type 2 diabetes mellitus
 
5–7
 
 and polycystic ovary
syndrome (PCOS), for which insulin resistance represents a key
pathological mechanism.
 
5–10
 
PCOS is a common disorder of premenopausal women characterized
by hyperandrogenism and substantial peripheral insulin resistance.
 
8,9
 
Hyperandrogenism results from increased androgen biosynthesis
and decreased SHBG synthesis, both associated with hyperinsulinaemia
and increased androgen bioavailability.
 
2,8,11,12
 
 Hyperandrogenism
may itself contribute to the development and maintenance of the
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insulin resistance state, which precedes and accompanies hyper-
insulinaemia and represents the probable link between the metabolic
syndrome, cardiovascular diseases and type 2 diabetes.
 
2,13
 
Several reviews report large numbers of trials investigating the
effects of metformin administration in women diagnosed with
PCOS.
 
14–20
 
 The most recent review, published in 2003, included trials
mostly uncontrolled and with small numbers of participants.
 
14–20
 
These focused on outcomes such as fertility, weight, blood pressure,
serum concentration of cholesterol and triglycerides, glycaemia and
circulating insulin.
Although some of these latter outcomes have led to metformin
use for the treatment of endocrinological diseases, the mechanisms
of action and the impact on endocrine hormones are not completely
understood. To our knowledge, no systematic review has evaluated
the extent to which metformin affects endogenous hormones
other than insulin. We conducted a systematic review and meta-
analysis of randomized controlled trials (RCTs) evaluating the effect
of metformin on endogenous hormone levels.
 
Methods
 
Literature search and selection
 
We used the OVID platform to search MEDLINE (January 1966
onwards), EMBASE (January 1980 onwards) and the Cochrane
Central Register of Controlled Trials Register (CENTRAL) (The
Cochrane Library, latest issue) until March 2007. The search strategy
combined terms for metformin with a search filter for RCTs (available
from the authors upon request). We also used the ‘Related Articles’
feature in PubMed to identify additional articles and screened the
reference lists of included studies without language restriction.
Included studies fulfilled the following criteria: RCTs investigating
metformin effects in women, and metformin given as a single
agent or as part of combined regimens including drugs other
than metformin and/or lifestyle modifications, as long as the
administrated co-interventions were the same in all groups within
each trial compared with placebo or no treatment. We included
RCTs reporting at least one post-treatment measure of blood and/
or urinary and/or salivary concentrations of at least one of the
following primary outcomes: total testosterone (TT), free testosterone
(FT), dehydroepiandrosteronesulfate (DHEAS), androstenedione
(ANDS) and SHBG. Secondary outcomes were fasting glycaemia and
insulinaemia. We excluded studies in pregnant or lactating women
and those with a loss to follow-up of more than 20%.
For trials with a cross-over design, we only included the first
post-intervention measurement (i.e. prior to cross-over). For
multi-arm RCTs, we included all pairwise comparisons for which the
two arms differed by metformin use only. For RCTs including
more than one population differing by indication for metformin
treatment, we considered the different populations separately.
 
Data extraction and quality assessment
 
Two reviewers independently screened the titles and abstracts of
the identified articles for potential eligibility, applying sensitive
criteria to the first evaluation. Because of poor agreement, a third
investigator evaluated all titles and abstracts that only a single
reviewer had judged as eligible. Two reviewers independently
screened the full text articles judged potentially eligible and then
used a piloted form for data extraction and methodological quality
assessment. They resolved disagreements by discussion with a third
reviewer. The data collected related to participants, intervention and
outcomes of interest. Methodological quality criteria included:
concealment of allocation, blinding, intention-to-treat (ITT) analyses,
and percentage of follow-up. If data were incomplete or unclear, we
made at least two attempts to contact the study investigators. We
included abstracts only if information related to methodological
aspects and study results were available.
 
Data analysis
 
We used the kappa statistic (
 
κ
 
) to evaluate the degree of agreement
between the two reviewers for titles and abstracts screening. We
then assessed raw agreement between the two reviewers for full text
eligibility and data extraction.
 
21
 
A priori, we defined the unadjusted analysis of post-treatment
measurements as primary analysis and the analysis adjusted for
baseline values as secondary analysis. For each of the outcomes we
calculated effect estimates using SI units (corresponding forest plot
figures available from the authors upon request).
We calculated the I
 
2
 
 statistic
 
22,23
 
 to assess heterogeneity across trial
results, applying the following interpretation for I
 
2
 
 (J. Higgins,
personal communication): 0–50 = low; 50–80 = moderate and
worthy of investigation; 80–100 = severe and worthy of under-
standing; 95–100 = aggregate with major caution. We explored
heterogeneity using preplanned subgroup analyses. The subgroups
were defined based on two different features, namely required
evidence of clinical and/or biochemical hyperandrogenism and
metformin administration as a single agent or as part of combined
regimens.
We conducted regression analyses to evaluate the effect on the
results of the use (
 
vs.
 
 no use) of placebos and adjusted for baseline
values. We assessed publication bias by visual inspection of funnel
plots (available from the authors upon request) that graphically
display the magnitude of each study effect estimates against the
inverse of the variance.
 
24
 
 We used Revman 4·2·7 and Stata version
8·2 (Stata Corp., College Station, TX, USA) for statistical analyses,
considering the weighted mean difference (WMD) as a measure of
effect for each outcome using the DerSimonian–Laird random
effects method.
 
Results
 
Systematic review flow
 
Figure 1 shows the trial flow. Twenty RCTs met the eligibility
criteria,
 
25–44
 
 accounting for 848 women. The degree of agreement
between the two reviewers was 0·435 (
 
κ
 
) for potential eligibility
(based on highly sensitive titles and abstracts screening) and 97%
(raw agreement) for full text eligibility and data extraction.
All the included trials reported measuring exclusively blood
concentration of the variables of interest. None of the included
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studies reported on outcomes measured on saliva or urine. Table 1
shows the characteristics of the included studies.
 
Methodological quality of included RCTs
 
The methodological quality varied among the included studies. All
but five of them reported on the randomization method.
 
29,36,37,39,40
 
Three RCTs provided no details regarding blinding,
 
34,36,39
 
 seven
reported blinding patients,
 
29,30,37,38,40,42,44
 
 two reported blinding
patients and investigators,
 
25,26
 
 two reported blinding patients and
caregivers,
 
27,43
 
 one reported blinding patients and outcome assessors,
 
28
 
one reported blinding investigators, caregivers, patients, outcome
assessors and manuscript writer,
 
35
 
 one reported blinding investigators,
caregivers, patients and outcome assessors,
 
41
 
 and one reported blinding
investigators.
 
33
 
 The remaining RCTs had an open-label design.
 
31,32
 
Only eight trials reported conducting ITT analyses.
 
28,31–34,37,39,43
 
 The
overall methodological quality was judged as acceptable.
 
Quantitative data synthesis
 
Pooling the WMDs for the post-treatment measurements from 11
studies,
 
27–34,36–38
 
 we found that metformin increased the circulating
levels of SHBG (WMD: 5·88 nmol/l, 95% CI 2·01–9·75, I
 
2
 
:
60·0%) (Fig. 2). The effects of metformin on the other variables
were not statistically significant. Heterogeneity decreased
(WMD: 9·04 nmol/l, 95% CI 1·05–17·03, I
 
2
 
: 28·3%) in subgroup
analyses including RCTs administering metformin as a single
agent.
 
25,26,31–33,37,43,44
 
Pooling the WMDs of the pre- to post-treatment changes
 
25–44
 
,
metformin decreased the circulating levels of TT (–0·38 nmol/l,
95% CI –0·51 to –0·25, I
 
2
 
: 9·4%), DHEAS (–0·50 
 
μ
 
mol/l, 95% CI
–0·83 to –0·16, I
 
2
 
: 0%) and ANDS (–1·39 nmol/l, 95% CI –2·30
to –0·49, I
 
2
 
: 38·6%), and increased the circulating levels of SHBG
(6·63 nmol/l, 95% CI 2·32–10·94, I
 
2
 
: 43·6%). The results were not
statistically significant for FT. Heterogeneity was statistically
significant only for SHBG (I
 
2
 
: 43·6, 
 
P
 
 = 0·04). Subgroup analyses
by administered treatment and by required evidence of hyper-
androgenism at the study entrance reduced heterogeneity for
SHBG (WMD: 12·30, 95% CI 6·30–8·30, I
 
2
 
: 0, 
 
P = 
 
0·0001 in subgroup
analyses by administered treatment). We also found evidence
of a very slight decrease in fasting glycaemia (–0·02 mmol/l, 95% CI
–0·03 to –0·01, I
 
2
 
: 0).
Sensitivity analyses of studies using placebo showed similar results
to those not using placebo. We produced funnel plots of the RCTs
for each of the investigated outcomes.
 
Discussion
 
In this systematic review, we found that, in both the primary and
secondary meta-analyses, metformin administration increased
Fig. 1 Flow diagram of the trial selection process.
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Table 1.
 
Characteristics of the included RCTs 
Study
Sample 
size
Total 
metformin 
dosage 
(mg/day) Control arm*
Duration of 
treatment 
(days) Participants’ characteristics
Baillargeon 
 
et al
 
. (2004)
 
25
 
128 1700 Placebo 180 Age range 17–40 PCOS
 
7
 
BMI 
 
≤ 
 
27 kg/m
 
2
 
Normal glucose tolerance
Not currently on OC or medications affecting insulin sensitivity
Chou 
 
et al
 
. (2003)
 
26
 
32 1500 Placebo 90 Age range 16–42 PCOS
 
8
 
BMI 
 
≤ 
 
30 kg/m
 
2
 
Normal glucose tolerance
Non-smokers Not on medications within the previous 3 months
Cibula 
 
et al.
 
 (2005)
 
27
 
30 1500 OC
 
1
 
180 Age range 18–28 PCOS
 
20
 
No secondary endocrine disorder or contraindications to OC use
Elter 
 
et al
 
. (2002)
 
28
 
40 1500 OC
 
1
 
 and diet 120 Age range 16–36 PCOS
 
9
 
BMI 
 
≤ 
 
26 kg/m
 
2
 
Normal glucose tolerance
Not on medications affecting carbohydrates or lipid metabolism within the previous 6 months
Gambineri 
 
et al
 
. (2004)
 
29
 
40 1700 Flutamide
 
2
 
 
and diet
180 Age range 21–33 PCOS
 
9
 
BMI 
 
≤ 
 
28 kg/m
 
2
 
Normal glucose tolerance
Not on medications within the previous 3 months Not on diet in previous 3 months
No significant body weight modifications in the previous 3 months
Gambineri 
 
et al
 
. (2006)
 
30
 
80 1700 Flutamide
 
2
 
 
and diet 
Placebo and diet
360 Age range 21–31 PCOS
 
17
 
BMI 
 
≤ 
 
28 kg/m
 
2
 
Reproductive age range 18–45
Waist circumference > 88 cm
 
19
 
Ibanez 
 
et al
 
. (2004)
 
31
 
24 850 No treatment 360 Age range 10–14 Low birthweight
 
10
 
BMI 
 
≤ 
 
26 kg/m
 
2
 
Precocious pubarche
 
11
 
Hyperinsulinaemia on a standard test
 
12
 
Normal glucose tolerance
No personal or familial history of diabetes mellitus Subclinical ovarian hyperandrogenism
 
13
 
Not currently on OC or any medication affecting gonadal function or carbohydrate metabolism
Ibanez 
 
et al
 
. (2004)
 
33
 
33 425 No treatment 180 Age range 7–8 Low birthweight
 
10
 
BMI 
 
≤ 
 
21 kg/m
 
2
 
Precocious pubarche
 
11
 
Hyperinsulinaemia on a standard test
 
12
 
Subclinical ovarian hyperandrogenism
 
13
 
No personal or familial history of diabetes mellitus Normal glucose tolerance
Not currently on OC or any medication affecting gonadal function or carbohydrate metabolism
Ibanez 
 
et al
 
. (2006)
 
32
 
38 425 No treatment 720 Age (mean) 8 Low birthweight
 
10
 
BMI 
 
≤ 
 
22 kg/m
 
2
 
Precocious pubarche
 
17
 
Khorram 
 
et al
 
. (2006)
 
34
 
31 1500 CC
 
3
 
21 Age range 26–28 PCOS
 
9
 
BMI > 29 kg/m
 
2
 
Normal glucose tolerance
Desire for fertility No previous assumption of CC
Kocak 
 
et al
 
. (2002)
 
35
 
56 1700 Placebo 
and CC
 
4
 
60 Age range 22–30 PCOS
 
9
 
Normal glucose tolerance
Documented history of resistance to CC
 
14
 
Not on OC or any medication affecting gonadal function or carbohydrate metabolism within the previous 3 months
Lv 
 
et al
 
. (2005)
 
36
 
50 500 CA
 
5
 
180 Age range 16–36 PCOS
 
9
 
BMI 
 
≤ 
 
25 kg/m
 
2
 
Normal glucose tolerance
Not on CC or any medications within the previous 6 months
Nestler 
 
et al
 
. (1998)
 
37
 
61 1500 Placebo 35 Age range 27–30 PCOS
 
9
 
BMI > 28 kg/m
 
2
 
Normal glucose tolerance
Not on CC or any medications within the previous 2 months
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Pasquali 
 
et al
 
. (2000)
 
38
 
40† 1700 Placebo 
and diet
180 Age range 23–38 PCOS
 
9
 
BMI > 28 kg/m
 
2
 
Not on CC or any medications within the previous 3 months
Refaie 
 
et al. (2005)39 55 1500 CC6 180 Age range 22–33 PCOS9
Sturrock et al. (2002)40 26 1500 Placebo 
and CC6
180 Age range 18–40 PCOS9 Documented history of resistance to CC14
Tang et al. (2006)41 143 1700 Placebo, 
physical 
exercise 
and diet
180 Age range: 18–39 PCOS9 BMI > 30 kg/m2 Normal glucose tolerance
Desire for fertility No previous ovulation induction therapy
No previous ovulation induction therapy
Not on hormone therapy currently/within the previous 6 weeks
Vandermolen et al. (2001)42 27 1500 Placebo 
and CC6
49 Age range 18–35 PCOS9
Documented history of resistance to CC14
van Santbrink et al. (2005)43 20 1700 Placebo 35 Age range 18–37 Desire for fertility Normal serum oestriol and FSH concentrations
Severe oligomenorrhoea or amenorrhoea Insulin resistance15
Documented history of resistance to CC14
Yarali et al. (2002)44 32 1700 Placebo 42 Age range 23–35 PCOS9 Documented history of resistance to CC14
No previous exogenous gonadotrophin treatment Normal glucose tolerance
Normal semen analysis No previous genital surgery
Normal hysterosalpingography and/or laparoscopy within the previous 6 months
*In each of the included RCTs, the control arm/s and the intervention arm/s differs/differ exclusively by metformin use.
†Recruited participants include 20 women diagnosed with PCOS, whose characteristics are described in this table and 20 controls comparable for age and weight, with regular menses and no evidence of 
hyperandrogenism.
1Oral contraceptive: ethinyl oestradiol (EE), 35 ng, and cyproterone acetate (CA), 2 mg for 21 days per month; 2flutamide at 500 mg/day; 3clomiphene citrate (CC), 100 mg/day on cycle days 5–9 only; 
4CC 100 mg/day on cycle days 3–7 only; 5CP, 1 tablet/day for 21 days/month from the first day of menstruation or progestin-induced bleeding; 6CC, 50 mg/day on cycle days 2–6 only; 7PCOS as defined 
by oligomenorrhoea and hyperandrogenaemia; 8PCOS as defined by oligomenorrhoea and hyperandrogenism; 9PCOS as defined by (i) ultrasound examination; (ii) oligomenorrhoea; (iii) manifestations of 
hyperandrogenism and/or hyperandrogenaemia; 10birthweight < –1.5 SD (corresponding to 2.7 kg at term in Catalonian girls); 11defined as having pubic hair at < 8 years of age; 12defined on a standard 2-h oral 
glucose tolerance test; 13defined as excessive response in terms of 17-hydroxyprogesterone to leuprolide acetate administration; 14documented history of resistance to CC ranging from 50 to 150 mg/day for 5 days; 
15defined as fasting glucose–insulin ratio < 4.5 mg/10–4 U; 16PCOS as defined by oligomenorrhoea or amenorrhoea and also at least one of the criteria of hyperandrogenism including a hirsutism score of > 7 
(according to Ferriman and Gallway) and/or an elevated serum concentration of free testosterone (> 4 ng/dl); 17attributed to exaggerated adrenarche; 18the diagnosis of PCOS included: chronic anovulation or 
severe oligomenorrhoea/amenorrhoea, hirsutism or total testosterone levels > 0.72 ng/ml; and polycystic ovarian morphology at ultrasound; 19consistent with an abdominal fat distribution phenotype; 
20PCOS as defined by oligomenorrhoea, increased concentration of at least one androgen above the upper reference limit and clinical manifestation of hyperandrogenism.
Study
Sample 
size
Total 
metformin 
dosage 
(mg/day) Control arm*
Duration of 
treatment 
(days) Participants’ characteristics
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SHBG circulating levels. In the secondary analysis, metformin
administration also lowered the circulating levels of TT, DHEAS and
ANDS.
This systematic review has the following strengths. We followed
the Cochrane Collaboration methods for conducting systematic
reviews and meta-analyses, including an extensive and systematic
search to identify all relevant trials without language restrictions.
However, we were unable to include two eligible trials in the
meta-analyses45,46 because relevant data were incompletely reported
or not provided by the authors.
There are some limitations to this review. All included participants
were premenopausal women, who were either at high risk of
developing, or had been diagnosed with, disorders affecting the
sexual steroid axis. Thus, our results limit inference regarding
metformin effects on circulating androgens and SHBG concen-
trations in healthy women.
 
          
          
            
          
             
           
            
          
          
          
          
              
            
              
                
               
              
              
                
   
 
  
  
   
 
  
 
   
 
Fig. 2 Meta-analysis of weighted mean differences in post-treatment circulating androgens and SHBG.
Metformin effects on circulating androgens and SHBG levels 667
© 2009 The Authors
Journal compilation © 2009 Blackwell Publishing Ltd, Clinical Endocrinology, 70, 661–670
 
 
  
  
 
   
  
  
 
 
   
  
  
   
   
  
   
  
   
   
  
   
    
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
    
   
   
   
    
      
    
   
 
   
    
   
  
 
   
   
     
Fig. 2 Continued.
668 M. Barba et al.
© 2009 The Authors
Journal compilation © 2009 Blackwell Publishing Ltd, Clinical Endocrinology, 70, 661–670
We observed low to moderate heterogeneity. The factors we specified
a priori as potential effect modifiers (required evidence of clinical
and/or biochemical hyperandrogenism, metformin administration
as a single agent or as part of combined regimens, and use vs. no use
of placebos) explained some of the observed heterogeneity.
The analysis of the characteristics of included studies revealed
additional factors that varied across studies and could potentially
explain heterogeneity. These factors include both characteristics of
the populations (i.e. diagnosis of PCOS, body mass index (BMI) at
inclusion) and of study design (i.e. methodology for measuring
circulating androgens, metformin therapy dosage and duration).
In fact, overweight and obese PCOS women are more likely to
exhibit severe hyperandrogenism and lower SHBG levels when
compared to their normal weight counterpart.47 Direct radio-
immunoassay (RIA) methods tend to show higher TT levels when
compared to studies using extraction and chromatography in
conjunction with RIA.29,41,48–50 There is also evidence that analogue-
based free testosterone RIA is highly unreliable. We conducted
post-hoc subgroup analyses based on these additional factors but
none of them reduced the heterogeneity.
Considerable experimental and epidemiological evidence
supports the association between circulating androgens and SHBG
levels and several life-threatening conditions in women. Elevated
serum levels of androgens are positively associated with breast cancer
risk, while SHBG levels are inversely associated with risk.51,52 Thus,
metformin could, by decreasing androgens levels and increasing
SHBG levels, have a potential role in the chemoprevention of breast
cancer. However, no clinical evidence is currently available to
support this hypothesis.
Androgens and SHBG have been also linked to adverse cardio-
vascular risk factors in women, with increased testosterone levels
and decreased SHBG levels strongly associated with central adiposity,
increased triglycerides, and decreased high density lipoprotein
(HDL) cholesterol levels. In fact, metformin has been shown to
decrease those cardiovascular risk factors such as blood pressure and
low density lipoprotein (LDL) cholesterol in PCOS.14 Although we
could not locate studies in non-diabetic patients, a systematic review
in patients with diabetes showed that metformin may prevent some
vascular complications, and mortality.53
Low levels of SHBG have also been associated with higher
rates of diabetes.54 This suggests a potential role of metformin in
preventing diabetes. Indeed, a systematic review has found evidence
that metformin may reduce the occurrence of type 2 diabetes.55
In summary, our systematic review and meta-analysis provides
evidence of metformin-induced changes in circulating androgens
and SHBG levels in women. The information is helpful for explaining
mechanisms related to metformin. The review indicates that a fairly
large amount of data from RCTs administering metformin in women
affected by PCOS or at risk of developing PCOS is currently available,
although the overall methodological quality is moderate. Conversely,
there are no data from RCTs regarding the effects of metformin in
healthy women. We thus suggest the use of metformin in future RCTs
focusing on patient-important outcomes, such those related to the role
of androgens as breast cancer promoters and potential mediators of
cardiovascular risk in women. We would further add the need for high-
quality studies, designed primarily to address the latter outcomes.
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